Amgen Settles Shareholder Suit Over Undisclosed $10.7B Tax Bill for $74 Million

Amgen's $74 Million Settlement Ends Investor Suit Over Concealed Tax Risks

Amgen has agreed to a $74 million settlement to resolve a shareholder lawsuit that claimed the biotechnology company deliberately delayed disclosing it could owe the Internal Revenue Service as much as $10.7 billion in back taxes and penalties. The proposed class action settlement, filed in Manhattan federal court on Monday, requires judicial approval and marks the end of a securities fraud claim that has weighed on the company since 2022.

The suit, led by the Asbestos Workers Philadelphia Pension Fund, centered on Amgen's tax practices between 2010 and 2015. The IRS alleged the company underpaid taxes by improperly shifting profits to a Puerto Rico subsidiary that manufactured many of its best-selling drugs. Although Puerto Rico is a U.S. territory, it is treated as a foreign jurisdiction for corporate tax purposes, a status that has long been used by pharmaceutical firms to reduce their domestic tax bills.

Shareholders argued that Amgen failed to adequately warn investors about the scale of the potential liability. The stock dropped 6.5% on August 4, 2021, and another 4.3% on April 28, 2022, after the company first detailed the IRS's demands in annual filings. Amgen had sought to have the case dismissed, but a federal judge rejected that motion in September 2024, paving the way for the settlement. Neither admitting nor denying wrongdoing, Amgen opted to end the litigation now, avoiding the distraction and cost of a trial.

The Unfinished Business: Why a $10.7 Billion Tax Bill Still Hangs Over Amgen

The settlement, while modest for a company with Amgen's $300 billion-plus market capitalization, is a reminder of the legal and reputational risks that can flow from how—and when—public companies disclose tax contingencies. But the far larger story remains unresolved: the IRS is still pursuing the $10.7 billion claim.

The Substance of the Tax Dispute

The core of the IRS case involves transfer pricing—the rules that govern how multinational corporations price transactions between their units in different tax jurisdictions. The government contends that Amgen's Puerto Rico operations, which manufacture top sellers like Prolia and Repatha, were assigned too much profit, reducing the company's taxable income in the United States. While such structures are common in the pharmaceutical industry, the IRS has aggressively challenged them in recent years, and Amgen's exposure is among the largest.

What the Settlement Signals

The $74 million payout is less than 1% of the $10.7 billion at stake in the IRS dispute, and it does not resolve the underlying tax bill. For shareholders, the settlement eliminates the overhang of the securities class action, but it leaves open the question of whether Amgen will ultimately have to pay billions to the government. The fact that the case survived a motion to dismiss and reached a settlement—even on preliminary terms—suggests that the allegations of defective disclosure had enough merit to impose a cost. From a governance perspective, it may prompt Amgen to strengthen its internal controls over the timing and detail of tax-related disclosures in future filings.

Broader Industry Implications

The Puerto Rico manufacturing model has been central to the cost structures of many blockbuster drugs. Amgen's case—if the IRS prevails—could embolden tax authorities in other jurisdictions to revisit similar arrangements. That raises the stakes for an industry already facing downward pressure on drug pricing and greater regulatory scrutiny. For now, however, the immediate impact is confined to Amgen, which must continue fighting the IRS while working to reassure investors that its financial statements fully reflect the risk.

What Amgen's Investors and Peers Should Watch Next

• For Amgen investors: The settlement removes the immediate litigation distraction, but the $10.7 billion IRS liability is still outstanding. Watch for quarterly disclosures on tax contingencies and any updates from the company regarding settlement negotiations with the IRS. A final resolution—whether a payment, a reduced settlement, or a court victory—will materially affect Amgen's balance sheet and future cash flows.
• For Amgen's management and board: The securities suit highlighted weaknesses in the timing and specificity of risk disclosures. Strengthening internal processes around tax contingency reporting and ensuring that material developments reach investors promptly will be essential to restoring trust and limiting future legal exposure.
• For pharmaceutical and other multinational companies with offshore profit-shifting structures: Review transfer-pricing documentation and consider whether current disclosures adequately convey the magnitude and probability of potential tax liabilities. Regulatory scrutiny of such arrangements is intensifying, and the Amgen situation illustrates how a large tax dispute can metastasize into a securities fraud claim if investors feel blindsided.